A Phase 1 interventional study of TAK-951 and Placebo in Healthy Volunteers, sponsored by Takeda. Terminated at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Feeling sick in the stomach (nausea) or throwing up (vomiting) are among the most common symptoms during treatment with medicines. It is hoped that a medicine called TAK-951 may help people to not feel sick in the stomach or throw up. The main aim of this study is to learn about side effects of TAK-951 when given as a single or multiple doses to healthy adults. Side effects are medical problems thought to be caused by the study treatment. Another aim is to learn how a healthy adult's body processes TAK-951 (this is called pharmacokinetics or PK). In this study, participants will receive either TAK-951 or placebo. The placebo looks like TAK-951 but does not have any medicine in it. Both TAK-951 and placebo will be given as an injection directly under the skin. This is called subcutaneous or subcutaneous (SC).
The study will be conducted in 3 parts:
Participants will be checked for their health either 28 days after the last injection (Parts 1 and 2) or 14 days after the last injection (Part 3).
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria
To be eligible for participation in this study, the participant must:
Meet the following requirements:
Is a female participant of nonchildbearing potential, defined by at least 1 of the following criteria:
Any participant who meets any of the following criteria will not qualify for entry into the study:
The participant has a history or presence of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single SC dose of TAK-951 matching placebo on Day 1.
Drug: Placebo
Participants will receive a single SC dose of TAK-951 Dose 1 on Day 1.
Drug: TAK-951
Participants will receive a single SC dose of TAK-951 Dose 2 on Day 1.
Drug: TAK-951
Participants will receive a single SC dose of TAK-951 Dose 3 on Day 1.
Drug: TAK-951
Participants will receive a single SC dose of TAK-951 Dose 4 on Day 1.
Drug: TAK-951
Participants will receive a single SC dose of TAK-951 Dose 5 on Day 1.
Drug: TAK-951
Participants will receive a single SC dose of TAK-951 Dose 6 on Day 1.
Drug: TAK-951
Participants will receive multiple rising SC doses of TAK-951 twice daily (BID) or 3 times a day (TID) in Part 2.
Drug: TAK-951
Participants will receive multiple rising SC doses of TAK-951 once daily (QD), BID, or TID from Days 1 to 5 followed by a washout period of 2 to 7 days and a single redose on any day from Days 8 to 13 in Part 3.
Drug: TAK-951
TAK-951 SC injection
TAK-951 matching placebo SC injection
Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, electrocardiogram (ECG), laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
Time frame: From the first dose of study drug up to Day 29 in Part 1
Part 2: Number of Participants With TEAEs
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
Time frame: From the first dose of study drug up to Day 33 in Part 2
Part 3: Number of Participants With TEAEs
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
Time frame: From the first dose of study drug up to Day 27 in Part 3
Part 2: Maximum Observed Plasma Concentration (Cmax) for TAK-951 on Day 1 of Drug Dosing
Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2
Part 2: Time of First Occurrence of Cmax (Tmax) for TAK-951 on Day 1 of Drug Dosing
Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2
Part 2: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) for TAK-951 on Day 1 of Drug Dosing
Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2
Part 2: AUCτ: Area Under the Plasma Concentration-time Curve During a Dosing Interval for TAK-951 on Day 1
Tau (τ) indicates the length of the dosing interval.
Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2
Part 2: AUCτ for TAK-951 at Steady State
τ indicates the length of the dosing interval.
Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 2
Part 2: AUC24 for TAK-951 at Steady State
Time frame: Predose on Day 1 and at multiple time points post-dose up to 24 hours on Day 1 in Part 2
Part 2: Cmax,ss: Maximum Observed Concentration at Steady State for TAK-951
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Tmax for TAK-951 at Steady State
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Terminal Disposition Phase Half-life (t1/2z) for TAK-951 at Steady State
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Apparent Clearance After Extravascular Administration (CL/F) for TAK-951 at Steady State
Apparent clearance after extravascular administration was to be calculated as Dose/AUCτ after multiple dosing.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration (Vz/F) for TAK-951 at Steady State
Apparent volume of distribution during the terminal disposition phase after extravascular administration was to be calculated as (CL/F)/λz at steady state, with λz as the terminal elimination rate constant.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Ctrough: Observed Plasma Concentration at the End of a Dosing Interval for TAK-951 at Steady State
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Rac[AUC]: Accumulation Ratio Based on AUCτ for TAK-951 at Steady State
Rac\[AUC\] was to be calculated as the ratio of AUCτ at steady state/AUCτ after a single dose.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 2: Rac[Cmax]: Accumulation Ratio Based on Cmax for TAK-951 at Steady State
Rac\[Cmax\] was to be calculated as the ratio of Cmax at steady state/Cmax after a single dose.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 7 in Part 2
Part 3: Number of Participants With AEs
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.
Time frame: From the re-treatment dose of study drug (any day from Days 8 to 13) up to Day 27 in Part 3
Part 1: Number of Participants Based on Antidrug Antibodies (ADA) Status in Serum
A 3-tiered ADA testing strategy was used in this study. A sample was initially screened for ADA by the ADA screening assay. Any positive sample in the screening assay was considered a potential positive, which was confirmed for true positivity by the confirmatory assay. If a sample was confirmed as an ADA true positive, ADA titer was assessed. ADA-positive was defined as participants who have confirmed positive ADA status in at least 1 postbaseline assessments. ADA-negative was defined as participants who did not have a confirmed positive ADA status in any postbaseline assessment. For ADA-positive only, high ADA titer was defined as participant who had at least 1 postbaseline ADA titer \>16; low ADA titer was defined as participant whose postbaseline ADA titers were all ≤16 and data is presented accordingly for each of these categories.
Time frame: Predose on Day 1 and post-dose on Days 14 and 29 in Part 1
Part 2: Number of Participants With ADA
Time frame: Predose on Day 1 and post-dose on Days 14 and 29 in Part 2
Part 3: Number of Participants With ADA
Time frame: Predose on Day 1 and post-dose on Days 14 and 29 in Part 3
Part 1: Cmax: Maximum Observed Plasma Concentration of TAK-951
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Part 1: AUC24: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours for TAK-951
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose and at multiple time points post-dose up to 24 hours on Day 1 in Part 1
Part 1: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-951
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Part 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration for TAK-951
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Part 1: Tmax: Time of First Occurrence of Cmax for TAK-951
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Part 1: t1/2z: Terminal Disposition Phase Half-life for TAK-951
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Part 1: CL/F: Apparent Clearance After Extravascular Administration of TAK-951
Apparent clearance after extravascular administration was calculated as Dose/AUC∞. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Part 1: Vz/F: Apparent Volume of Distribution During the Terminal Disposition Phase After Extravascular Administration
Apparent volume of distribution during the terminal disposition phase after extravascular administration was calculated as (CL/F)/λz, where λz is the terminal elimination rate constant. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Time frame: Predose on Day 1 and at multiple time points post-dose up to Day 3 in Part 1
Participants took part in the study at 2 investigative sites in the United States from 7 January 2022 to 21 September 2023.
| Milestone | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 0 |
| Completed | 12 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, electrocardiogram (ECG), laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
| Participants | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 |
|---|---|---|---|---|---|---|---|
| Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 6 | 4 | 5 | 6 | 5 | 4 | 6 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
No measurements were reported for this outcome.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug.
No measurements were reported for this outcome.
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Apparent clearance after extravascular administration was calculated as Dose/AUC∞. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
Apparent volume of distribution during the terminal disposition phase after extravascular administration was calculated as (CL/F)/λz, where λz is the terminal elimination rate constant. Due to confidentiality reasons and chances of exposing the doses for TAK-951, the data for this pharmacokinetic outcome measure was not reported.
Results for this outcome have not been posted.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Tau (τ) indicates the length of the dosing interval.
No measurements were reported for this outcome.
τ indicates the length of the dosing interval.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Apparent clearance after extravascular administration was to be calculated as Dose/AUCτ after multiple dosing.
No measurements were reported for this outcome.
Apparent volume of distribution during the terminal disposition phase after extravascular administration was to be calculated as (CL/F)/λz at steady state, with λz as the terminal elimination rate constant.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Rac\[AUC\] was to be calculated as the ratio of AUCτ at steady state/AUCτ after a single dose.
No measurements were reported for this outcome.
Rac\[Cmax\] was to be calculated as the ratio of Cmax at steady state/Cmax after a single dose.
No measurements were reported for this outcome.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug. An AE can be any unfavorable and unintended sign (including physical examinations, vital signs, ECG, laboratory assessment findings), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.
No measurements were reported for this outcome.
A 3-tiered ADA testing strategy was used in this study. A sample was initially screened for ADA by the ADA screening assay. Any positive sample in the screening assay was considered a potential positive, which was confirmed for true positivity by the confirmatory assay. If a sample was confirmed as an ADA true positive, ADA titer was assessed. ADA-positive was defined as participants who have confirmed positive ADA status in at least 1 postbaseline assessments. ADA-negative was defined as participants who did not have a confirmed positive ADA status in any postbaseline assessment. For ADA-positive only, high ADA titer was defined as participant who had at least 1 postbaseline ADA titer \>16; low ADA titer was defined as participant whose postbaseline ADA titers were all ≤16 and data is presented accordingly for each of these categories.
| Participants | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 |
|---|---|---|---|---|---|---|---|
| Day 1: Negative | 12 | 6 | 6 | 6 | 5 | 6 | 6 |
| Day 1: Positive: Low Titer | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Day 1: Positive: High Titer | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 14: Negative | 12 | 6 | 6 | 6 | 5 | 6 | 6 |
| Day 14: Positive: Low Titer | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Day 14: Positive: High Titer | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 29: Negative | 12 | 6 | 6 | 6 | 5 | 6 | 6 |
| Day 29: Positive: Low Titer | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Day 29: Positive: High Titer | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From the first dose of study drug up to Day 29 in Part 1. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Pooled Placebo | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Part 1, Cohort 1: TAK-951 Dose 1 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1, Cohort 2: TAK-951 Dose 2 | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part 1, Cohort 3: TAK-951 Dose 3 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 1, Cohort 4: TAK-951 Dose 4 | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Part 1, Cohort 5: TAK-951 Dose 5 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part 1, Cohort 6: TAK-951 Dose 6 | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 |
|---|---|---|---|---|---|---|---|
| SyncopeNervous system disorders | 0/12 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Event | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 |
|---|---|---|---|---|---|---|---|
| TachycardiaCardiac disorders | 2/12 | 2/6 | 2/6 | 5/6 | 2/6 | 4/6 | 5/6 |
| Orthostatic hypotensionVascular disorders | 0/12 | 1/6 | 1/6 | 1/6 | 3/6 | 2/6 | 0/6 |
| Injection site reactionGeneral disorders | 0/12 | 0/6 | 2/6 | 2/6 | 0/6 | 0/6 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/12 | 0/6 | 2/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| PresyncopeNervous system disorders | 0/12 | 0/6 | 0/6 | 2/6 | 2/6 | 0/6 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Blood creatine phosphokinase increasedInvestigations | 0/12 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| DizzinessNervous system disorders | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| Dry mouthGastrointestinal disorders | 0/12 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 |
The Safety Analysis Set included all participants who were randomized and received at least 1 dose of study treatment. This study was terminated after completion of Part 1 following the Sponsor's decision attributed to the benefit-risk profile derived from the Part 1 data. Hence, no participants were enrolled in Parts 2 and 3.
| Age, Continuous(years) | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.36 ± 10.68 | 34.5 ± 10.07 | 35.2 ± 5.91 | 31.7 ± 9.71 | 30.0 ± 8.92 | 28.0 ± 11.10 | 40.2 ± 10.09 | — | — | 33.3 ± 9.78 |
| Sex: Female, Male(Participants) | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 0 | 2 | 0 | 2 | 3 | 0 | 0 | 10 |
| Male | 10 | 5 | 6 | 4 | 6 | 4 | 3 | 0 | 0 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 5 | 0 | 2 | 2 | 1 | 1 | 2 | 0 | 0 | 13 |
| Ethnicity — Not Hispanic or Latino | 7 | 6 | 4 | 4 | 5 | 5 | 4 | 0 | 0 | 35 |
| Ethnicity — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Pooled Placebo | Part 1, Cohort 1: TAK-951 Dose 1 | Part 1, Cohort 2: TAK-951 Dose 2 | Part 1, Cohort 3: TAK-951 Dose 3 | Part 1, Cohort 4: TAK-951 Dose 4 | Part 1, Cohort 5: TAK-951 Dose 5 | Part 1, Cohort 6: TAK-951 Dose 6 | Part 2, TAK-951 Multiple Rising Dose Cohort | Part 3, TAK-951 Multiple Dose Titration Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — Asian | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race — Black or African American | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 5 |
| Race — White | 8 | 4 | 3 | 4 | 6 | 5 | 6 | 0 | 0 | 36 |
| Race — More than one race | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Race — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2022 to primary completion in Sep 2023, 20 months.
Results were first posted in Nov 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TAK-951